SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0302 2838 OR L773:1873 7560 ;pers:(Sjödahl Gottfrid)"

Sökning: L773:0302 2838 OR L773:1873 7560 > Sjödahl Gottfrid

  • Resultat 1-10 av 16
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Aine, Mattias, et al. (författare)
  • On Molecular Classification of Bladder Cancer: Out of One, Many.
  • 2015
  • Ingår i: European Urology. - : Elsevier BV. - 1873-7560 .- 0302-2838. ; 68:6, s. 921-923
  • Tidskriftsartikel (refereegranskat)abstract
    • Comparative analysis showed that bladder cancer classification systems identify overlapping subtypes but at different levels. Muscle-invasive bladder cancer shows remarkable heterogeneity, and six subtypes were identified that differ in transcriptional networks, marker profiles, and expression of actionable targets.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  •  
6.
  • Sjödahl, Gottfrid, et al. (författare)
  • Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
  • 2022
  • Ingår i: European Urology. - : Elsevier BV. - 0302-2838 .- 1873-7560. ; 81:5, s. 523-532
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available for clinical use to predict response to neoadjuvant chemotherapy.OBJECTIVE: To investigate how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy.DESIGN, SETTING, AND PARTICIPANTS: Classification of a retrospective cohort of 149 patients was performed by tumor transcriptomic profiling and immunostaining. A cohort treated with radical cystectomy alone and public data sets were used for comparison and external validation.OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Complete pathological response in the cystectomy specimen (ypT0N0) and survival were compared in predefined molecular subtypes. Differential gene expression and chemotherapy response were explored beyond molecular subtypes.RESULTS AND LIMITATIONS: Patients with genomically unstable (GU) and urothelial-like (Uro) tumors had higher proportions of complete pathological response (16/31 [52%] and 17/54 [31%]), versus five out of 24 (21%) with the basal/squamous (Ba/Sq) subtype following neoadjuvant chemotherapy and radical cystectomy. Molecular subtype was independently associated with improved survival for patients with GU tumors (hazard ratio [HR] 0.29, 95% confidence interval [CI]: 0.11-0.79) and UroC tumors (HR 0.37, 95% CI: 0.14-0.94) compared with Ba/Sq tumors, adjusting for clinical stage. In addition, expression of the gene coding for osteopontin (SPP1) showed a subtype-dependent effect on chemotherapy response.CONCLUSIONS: Urothelial cancer of the luminal-like (GU and Uro) subtypes is more responsive to cisplatin-based neoadjuvant chemotherapy. A second-generation of subtype-specific biomarkers, for example, SPP1, may be a way forward to develop a more precision-based treatment approach for neoadjuvant chemotherapy in MIBC.PATIENT SUMMARY: This study shows that tumor classification by gene expression profiling and molecular subtyping can identify patients who are more likely to benefit from chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Together with other markers for response, molecular subtypes could have a role in selective administration of such chemotherapy.
  •  
7.
  • Sjödahl, Gottfrid, et al. (författare)
  • Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
  • 2022
  • Ingår i: European urology. - : Elsevier. - 1873-7560 .- 0302-2838. ; 81:5, s. 523-532
  • Tidskriftsartikel (refereegranskat)abstract
    • For muscle-invasive bladder cancer (MIBC), no tissue biomarkers are available for clinical use to predict response to neoadjuvant chemotherapy.To investigate how molecular subtypes impact pathological response and survival in patients receiving preoperative cisplatin-based chemotherapy.Classification of a retrospective cohort of 149 patients was performed by tumor transcriptomic profiling and immunostaining. A cohort treated with radical cystectomy alone and public data sets were used for comparison and external validation.Complete pathological response in the cystectomy specimen (ypT0N0) and survival were compared in predefined molecular subtypes. Differential gene expression and chemotherapy response were explored beyond molecular subtypes.Patients with genomically unstable (GU) and urothelial-like (Uro) tumors had higher proportions of complete pathological response (16/31 [52%] and 17/54 [31%]), versus five out of 24 (21%) with the basal/squamous (Ba/Sq) subtype following neoadjuvant chemotherapy and radical cystectomy. Molecular subtype was independently associated with improved survival for patients with GU tumors (hazard ratio [HR] 0.29, 95% confidence interval [CI]: 0.11-0.79) and UroC tumors (HR 0.37, 95% CI: 0.14-0.94) compared with Ba/Sq tumors, adjusting for clinical stage. In addition, expression of the gene coding for osteopontin (SPP1) showed a subtype-dependent effect on chemotherapy response.Urothelial cancer of the luminal-like (GU and Uro) subtypes is more responsive to cisplatin-based neoadjuvant chemotherapy. A second-generation of subtype-specific biomarkers, for example, SPP1, may be a way forward to develop a more precision-based treatment approach for neoadjuvant chemotherapy in MIBC.This study shows that tumor classification by gene expression profiling and molecular subtyping can identify patients who are more likely to benefit from chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Together with other markers for response, molecular subtypes could have a role in selective administration of such chemotherapy.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 16
Typ av publikation
tidskriftsartikel (16)
Typ av innehåll
refereegranskat (13)
övrigt vetenskapligt/konstnärligt (3)
Författare/redaktör
Liedberg, Fredrik (13)
Eriksson, Pontus (12)
Höglund, Mattias (11)
Kollberg, Petter (6)
Aine, Mattias (6)
visa fler...
Chebil, Gunilla (5)
Lövgren, Kristina (4)
Abrahamsson, Johan (3)
Gudjonsson, Sigurdur (3)
Lauss, Martin (3)
Black, Peter C. (3)
Bernardo, Carina (3)
Marzouka, Nour al da ... (3)
Hoadley, Katherine A (3)
Choi, Woonyoung (3)
McConkey, David J. (3)
Kim, William Y. (3)
Lerner, Seth P. (3)
Hultman Patschan, Ol ... (3)
Olsson, Hans (2)
Fernö, Mårten (2)
Powles, Thomas (2)
Bellmunt, Joaquim (2)
Ullén, Anders (2)
Månsson, Wiking (2)
Hartmann, Arndt (2)
Real, Francisco X. (2)
Malats, Nuria (2)
Al-Ahmadie, Hikmat (2)
Johansson, Iva (2)
Groeneveld, Clarice ... (2)
Castro, Mauro A.A. (2)
Dyrskjøt, Lars (2)
Allory, Yves (2)
Radvanyi, François (2)
Engilbertsson, Helgi (1)
Lindgren, David (1)
Kim, Jaegil (1)
Cwikiel, Magdalena (1)
van Rhijn, Bas W.G. (1)
Ullen, A (1)
Wright, Jonathan (1)
Robertson, A Gordon (1)
Weinstein, John N (1)
Boormans, Joost L. (1)
Zwarthoff, Ellen C. (1)
Lebret, Thierry (1)
Holmsten, K (1)
Todenhöfer, Tilman (1)
visa färre...
Lärosäte
Lunds universitet (15)
Linköpings universitet (2)
Göteborgs universitet (1)
Karolinska Institutet (1)
Språk
Engelska (16)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (16)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy